HARVARD BIOSCIENCE INC Form 8-K October 27, 2016		
UNITED STATES SECURITIES AND EXCHANGE CO Washington, D.C. 20549	OMMISSION	
Form 8-K		
CURRENT REPORT		
Pursuant to Section 13 or 15(d) of the	e Securities Exchange Act of 1934	
Date of Repor	rt (Date of earliest event Reported): Oct	tober 27, 2016
(Exac	HARVARD BIOSCIENCE, INC. et Name of Registrant as Specified in C	'harter)
<b>Delaware</b> (State or Other Jurisdiction of Incorporation)	<b>001-33957</b> (Commission File Number)	<b>04-3306140</b> (I.R.S. Employer Identification Number)
84 October Hill Road, Hollisto (Address of Principal Executive Off (Regis		ea code)
(Former na	ame or former address, if changed since	e last report)
Check the appropriate box below if the the registrant under any of the followin	<del>-</del>	neously satisfy the filing obligation of
]	o Rule 425 under the Securities Act (17)	

[ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

#### Item 2.02. Results of Operations and Financial Condition.

On October 27, 2016, Harvard Bioscience, Inc. issued a press release announcing financial results for the three and nine months ended September 30, 2016 and the details of a related conference call to be held at 4:30 PM EST on October 27, 2016. The press release is furnished as Exhibit 99.1 and incorporated herein by reference.

The information in Item 2.02 of this Current Report on Form 8-K and Exhibit 99.1 attached hereto shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

#### Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

Exhibit <u>Number</u>	Title
99.1	Press release of Harvard Bioscience, Inc. issued on October 27, 2016.

#### **SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

## HARVARD BIOSCIENCE, INC.

Date: October 27, 2016 By: /s/ Robert E. Gagnon

Robert E. Gagnon Chief Financial Officer

# **INDEX TO EXHIBITS**

Exhibit <u>Number</u>	Description of Exhibit
99.1	Press Release issued by Harvard Bioscience, Inc. on October 27, 2016.